XBiotech Shares Climb Nearly 8% in After Hours As Sale of Bermekimab Closes

Date : 12/30/2019 @ 10:08PM
Source : Dow Jones News
Stock : Johnson and Johnson (JNJ)
Quote : 139.76  0.0 (0.00%) @ 12:15PM
Last Trade
Last $ 142.47 ▲ 2.71 (1.94%)

XBiotech Shares Climb Nearly 8% in After Hours As Sale of Bermekimab Closes

Historical Stock Chart

6 Months : From Oct 2019 to Apr 2020

Click Here for more XBiotech Charts.
   By Stephen Nakrosis 

Shares of XBiotech Inc. (XBIT) are moving higher in Monday's after-hours market, after the company said it closed the sale of its True Human Antibody Bermekimab to Janssen Biotech Inc.

Janssen Biotech is a unit of Johnson & Johnson.

XBiotech said it received $750 million and could receive up to $600 million more upon completion of certain commercialization authorizations if Janssen pursues Bermekimab indications outside dermatology.

XBiotech said it remains free to use its True Human Antibody discovery program to develop other therapies.

At 4:27 p.m. EST, XBiotech shares had risen 7.68% to trade at $20.98, on volume of just over 1,300 shares.


--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com


(END) Dow Jones Newswires

December 30, 2019 16:53 ET (21:53 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest JNJ Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.